<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00777790</url>
  </required_header>
  <id_info>
    <org_study_id>MTA19</org_study_id>
    <nct_id>NCT00777790</nct_id>
  </id_info>
  <brief_title>Study of a Booster Dose of Meningococcal Diphtheria Toxoid Conjugate Vaccine in Adolescents</brief_title>
  <official_title>Antibody Responses to a Booster Dose of an Experimental Tetravalent (A, C, Y, and W-135) Meningococcal Diphtheria Toxoid Conjugate Vaccine, Menactra® in Adolescents Who Previously Received Menomune® or Menactra®</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi Pasteur, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study was designed to evaluate the antibody response to a Menactra® booster dose in
      participants who previously received one dose of Menactra® or Menomune® as adolescents 3
      years earlier in Study MTA02.

      Primary Objective:

      To evaluate the antibody responses to a booster dose of a tetravalent meningococcal
      diphtheria toxoid conjugate vaccine (Menactra®) in participants who had previously received
      Menactra® or Menomune® as adolescents in the MTA02 Study and antibody responses to a dose of
      Menactra® in naive adolescents.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All subjects were given a single boosting dose of Menactra® to evaluate the kinetics of the
      response, the magnitude and the avidity of the antibody produced.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2004</start_date>
  <completion_date type="Actual">April 2005</completion_date>
  <primary_completion_date type="Actual">April 2004</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Geometric Mean Titers (GMTs) of Serum Bactericidal Activity for Each of the 4 Vaccine Serogroups.</measure>
    <time_frame>Day 0 and 8 and 28 days post-vaccination</time_frame>
    <description>Geometric mean titers and their 95% confidence interval of serum bactericidal activity for the 4 vaccine serogroups before vaccination, at 8 days post- and 28 days post-booster dose of Menactra vaccine or a primary dose of Menactra vaccine in the meningococcal vaccine-naïve Control group.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">241</enrollment>
  <condition>Meningitis</condition>
  <condition>Meningococcemia</condition>
  <arm_group>
    <arm_group_label>Menactra® Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Received Menactra® vaccine in Study MTA02</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Menomune® Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Received Menomune® vaccine in Study MTA02</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Meningococcal vaccine-naïve Control Group.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Meningococcal Polysaccharide Diphtheria Toxoid Conjugate</intervention_name>
    <description>0.5 mL, Intramuscular</description>
    <arm_group_label>Menactra® Group</arm_group_label>
    <other_name>Menactra®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Meningococcal Polysaccharide Diphtheria Toxoid Conjugate</intervention_name>
    <description>0.5 mL, Intramuscular</description>
    <arm_group_label>Menomune® Group</arm_group_label>
    <other_name>Menactra®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Meningococcal Polysaccharide Diphtheria Toxoid Conjugate</intervention_name>
    <description>0.5 mL, Intramuscular</description>
    <arm_group_label>Control Group</arm_group_label>
    <other_name>Mneactra®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria :

          -  Participant is healthy, as determined by medical history and physical examination.

          -  Participant is at least 13 years of age but not yet 22 years of age at time of
             enrollment.

          -  For the Menactra® and Menomune® groups, participant received one dose of Menactra® or
             Menomune® in MTA02 trial and completed trial (2 blood samples, contacted for Month 6
             safety follow up).

          -  For the Control group, participant has no previous history of any meningococcal
             vaccination.

          -  If &lt; 18 years of age, participant has signed Institutional Review Board (IRB) approved
             informed assent form and his/her parent/legal guardian has signed an IRB-approved
             informed consent form.

          -  If ≥ 18 years of age, participant has signed an IRB-approved informed consent form.

          -  Able to provide vaccination log.

        Exclusion Criteria :

          -  Serious chronic disease (i.e., cardiac, renal, neurologic, metabolic, rheumatologic,
             psychiatric etc).

          -  Known or suspected impairment of immunologic function.

          -  Acute medical illness with or without fever within the last 72 hours or an oral
             temperature ≥ 100.4ºF (≥ 38.0ºC) at the time of inclusion.

          -  For the Menactra® and Menomune® groups, history of documented invasive meningococcal
             disease or previous meningococcal vaccination with the exception of meningococcal
             vaccination given as part of MTA02 trial.

          -  For the Control group, history of documented invasive meningococcal disease or
             previous meningococcal vaccination.

          -  Administration of immune globulin, other blood products within the last three months,
             injected or oral corticosteroids or other immunomodulatory therapy within six weeks of
             the study vaccine. Individuals on a tapering dose schedule of oral steroids lasting &lt;
             7 days may be included in the trial as long as they have not received more than one
             course within the last two weeks prior to enrollment.

          -  Antibiotic therapy within the 72 hours prior to vaccination or antibiotic therapy
             within the 72 hours prior to having any blood sample drawn.

          -  Received any vaccine in the 14-day period prior to study vaccination, or scheduled to
             receive any vaccination during the 14-day period after study vaccination.

          -  Suspected or known hypersensitivity to any of the vaccine components.

          -  Unavailable for the entire study period or unable to attend the scheduled visits or to
             comply with the study procedures.

          -  In females, a positive or equivocal urine pregnancy test at the time of vaccination.

          -  Enrolled in another clinical trial.

          -  Any condition, which, in the opinion of the investigator, would pose a health risk to
             the participant, or interfere with the evaluation of the vaccine.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi Pasteur Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30062</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Woburn</city>
        <state>Massachusetts</state>
        <zip>01801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Akron</city>
        <state>Ohio</state>
        <zip>44308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sellersville</city>
        <state>Pennsylvania</state>
        <zip>18960</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kingsport</city>
        <state>Tennessee</state>
        <zip>37660</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.sanofipasteur.com</url>
  </link>
  <link>
    <url>http://www.sanofi.com</url>
  </link>
  <results_reference>
    <citation>Keyserling H, Papa T, Koranyi K, Ryall R, Bassily E, Bybel MJ, Sullivan K, Gilmet G, Reinhardt A. Safety, immunogenicity, and immune memory of a novel meningococcal (groups A, C, Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine (MCV-4) in healthy adolescents. Arch Pediatr Adolesc Med. 2005 Oct;159(10):907-13.</citation>
    <PMID>16203934</PMID>
  </results_reference>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 21, 2008</study_first_submitted>
  <study_first_submitted_qc>October 21, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 22, 2008</study_first_posted>
  <results_first_submitted>December 2, 2008</results_first_submitted>
  <results_first_submitted_qc>February 18, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 19, 2009</results_first_posted>
  <last_update_submitted>January 21, 2014</last_update_submitted>
  <last_update_submitted_qc>January 21, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 14, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Meningitis</keyword>
  <keyword>Meningococcemia</keyword>
  <keyword>Neisseria meningitidis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Meningitis</mesh_term>
    <mesh_term>Diphtheria</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were recruited from 20 February 2004 to 08 April 2004 at 9 medical clinics in the US.</recruitment_details>
      <pre_assignment_details>A total of 241 subjects that met the inclusion criteria were enrolled and vaccinated.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Menactra® Group</title>
          <description>Subjects that received Menactra® vaccine in Study MTA02</description>
        </group>
        <group group_id="P2">
          <title>Menomune® Group</title>
          <description>Subjects that received Menomune® vaccine in Study MTA02</description>
        </group>
        <group group_id="P3">
          <title>Control Group</title>
          <description>Meningococcal vaccine-naïve subjects</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="76"/>
                <participants group_id="P2" count="77"/>
                <participants group_id="P3" count="88"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="76"/>
                <participants group_id="P2" count="77"/>
                <participants group_id="P3" count="88"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Menactra® Group</title>
          <description>Subjects that received Menactra® vaccine in Study MTA02</description>
        </group>
        <group group_id="B2">
          <title>Menomune® Group</title>
          <description>Subjects that received Menomune® vaccine in Study MTA02</description>
        </group>
        <group group_id="B3">
          <title>Control Group</title>
          <description>Meningococcal vaccine-naïve subjects</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="76"/>
            <count group_id="B2" value="77"/>
            <count group_id="B3" value="88"/>
            <count group_id="B4" value="241"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56"/>
                    <measurement group_id="B2" value="57"/>
                    <measurement group_id="B3" value="68"/>
                    <measurement group_id="B4" value="181"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16.6" spread="1.91"/>
                    <measurement group_id="B2" value="16.8" spread="1.85"/>
                    <measurement group_id="B3" value="15.7" spread="1.97"/>
                    <measurement group_id="B4" value="16.4" spread="1.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="44"/>
                    <measurement group_id="B4" value="105"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="46"/>
                    <measurement group_id="B3" value="44"/>
                    <measurement group_id="B4" value="136"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="76"/>
                    <measurement group_id="B2" value="77"/>
                    <measurement group_id="B3" value="88"/>
                    <measurement group_id="B4" value="241"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Titers (GMTs) of Serum Bactericidal Activity for Each of the 4 Vaccine Serogroups.</title>
        <description>Geometric mean titers and their 95% confidence interval of serum bactericidal activity for the 4 vaccine serogroups before vaccination, at 8 days post- and 28 days post-booster dose of Menactra vaccine or a primary dose of Menactra vaccine in the meningococcal vaccine-naïve Control group.</description>
        <time_frame>Day 0 and 8 and 28 days post-vaccination</time_frame>
        <population>GMT results were on the per-protocol population for immunogenicity.</population>
        <group_list>
          <group group_id="O1">
            <title>Menactra® Group</title>
            <description>Subjects that received Menactra® vaccine in Study MTA02</description>
          </group>
          <group group_id="O2">
            <title>Menomune® Group</title>
            <description>Subjects that received Menomune® vaccine in Study MTA02</description>
          </group>
          <group group_id="O3">
            <title>Control Group</title>
            <description>Meningococcal vaccine-naïve subjects</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titers (GMTs) of Serum Bactericidal Activity for Each of the 4 Vaccine Serogroups.</title>
          <description>Geometric mean titers and their 95% confidence interval of serum bactericidal activity for the 4 vaccine serogroups before vaccination, at 8 days post- and 28 days post-booster dose of Menactra vaccine or a primary dose of Menactra vaccine in the meningococcal vaccine-naïve Control group.</description>
          <population>GMT results were on the per-protocol population for immunogenicity.</population>
          <units>Titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
                <count group_id="O2" value="72"/>
                <count group_id="O3" value="84"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serogroup A (Day 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1075.2" lower_limit="763.6" upper_limit="1514.1"/>
                    <measurement group_id="O2" value="193.6" lower_limit="113.7" upper_limit="329.9"/>
                    <measurement group_id="O3" value="83.3" lower_limit="47.3" upper_limit="146.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup A (Day 8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9300.5" lower_limit="7539.3" upper_limit="11473.2"/>
                    <measurement group_id="O2" value="4423.9" lower_limit="3272.7" upper_limit="5980.0"/>
                    <measurement group_id="O3" value="12897.1" lower_limit="9908.1" upper_limit="16787.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup A (Day 28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4300.9" lower_limit="3408.5" upper_limit="5427.0"/>
                    <measurement group_id="O2" value="3219.9" lower_limit="2413.6" upper_limit="4295.5"/>
                    <measurement group_id="O3" value="6239.2" lower_limit="4922.7" upper_limit="7907.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup C (Day 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="246.2" lower_limit="139.2" upper_limit="435.5"/>
                    <measurement group_id="O2" value="124.4" lower_limit="65.9" upper_limit="234.8"/>
                    <measurement group_id="O3" value="39.7" lower_limit="24.1" upper_limit="65.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup C (Day 8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17888.7" lower_limit="14004.2" upper_limit="22850.7"/>
                    <measurement group_id="O2" value="1149.4" lower_limit="692.8" upper_limit="1907.0"/>
                    <measurement group_id="O3" value="7003.3" lower_limit="4979.4" upper_limit="9849.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup C (Day 28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8601.8" lower_limit="6552.2" upper_limit="11292.6"/>
                    <measurement group_id="O2" value="664.0" lower_limit="396.3" upper_limit="1112.5"/>
                    <measurement group_id="O3" value="2802.3" lower_limit="1932.3" upper_limit="4063.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup Y (Day 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="570.0" lower_limit="353.9" upper_limit="918.3"/>
                    <measurement group_id="O2" value="398.6" lower_limit="259.8" upper_limit="611.7"/>
                    <measurement group_id="O3" value="204.3" lower_limit="131.4" upper_limit="317.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup Y (Day 8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13088.9" lower_limit="9486.0" upper_limit="18060.2"/>
                    <measurement group_id="O2" value="3098.2" lower_limit="2170.0" upper_limit="4423.4"/>
                    <measurement group_id="O3" value="7061.3" lower_limit="5029.8" upper_limit="9913.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup Y (Day 28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5821.0" lower_limit="4140.6" upper_limit="8183.3"/>
                    <measurement group_id="O2" value="2489.6" lower_limit="1786.5" upper_limit="3469.3"/>
                    <measurement group_id="O3" value="4411.8" lower_limit="3117.8" upper_limit="6242.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup W-135 (Day 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="451.0" lower_limit="300.2" upper_limit="677.4"/>
                    <measurement group_id="O2" value="126.8" lower_limit="80.0" upper_limit="200.9"/>
                    <measurement group_id="O3" value="23.0" lower_limit="15.7" upper_limit="33.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup W-135 (Day 8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9861.6" lower_limit="7442.9" upper_limit="13066.4"/>
                    <measurement group_id="O2" value="2008.9" lower_limit="1516.2" upper_limit="2661.9"/>
                    <measurement group_id="O3" value="6036.6" lower_limit="4555.5" upper_limit="7999.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup W-135 (Day 28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4882.9" lower_limit="3712.1" upper_limit="6422.9"/>
                    <measurement group_id="O2" value="1625.5" lower_limit="1250.6" upper_limit="2112.8"/>
                    <measurement group_id="O3" value="3018.3" lower_limit="2369.7" upper_limit="3844.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events data were collected from the day of vaccination for 28 days post-vaccination.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Menactra® Group</title>
          <description>Subjects that received Menactra® vaccine in Study MTA02</description>
        </group>
        <group group_id="E2">
          <title>Menomune® Group</title>
          <description>Subjects that received Menomune® vaccine in Study MTA02</description>
        </group>
        <group group_id="E3">
          <title>Control Group</title>
          <description>Meningococcal vaccine-naïve subjects</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="88"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 6.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="88"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Dysmenorrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="77"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="88"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pharyngolaryngeal pain</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="76"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="77"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="88"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Director</name_or_title>
      <organization>Sanofi Pasteur Inc.</organization>
      <email>RegistryContactUs@sanofipasteur.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

